Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma (imMUno)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Condition or disease
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Patients with metastatic uveal melanoma.
Patients with metastatic uveal melanoma
Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment
Antecedent of another evolutionary tumor pathology